At the time of sampling, national antimalarial treatment guidelines in Afghanistan recommended chloroquine as the first-line treatment of P. vivax (alongside a 14-day course of primaquine, where the G6PD status of the patient can be ascertained) as well as for cases of unconfirmed malaria. This evidence concerns the gene G6PD and malaria.